Alba Therapeutics in Washington Post

 
8/18/2008

A new research study presented at the Digestive Disease Week meeting in San Diego found that a medicine called AT-1001 may protect celiac disease patients from exposure to gluten by preventing gluten from crossing the intestinal mucosa. In a second study at the meeting, researchers concluded that the current criteria for diagnosing celiac is too stringent, resulting in many patients going undiagnosed and untreated.
www.washingtonpost.com/wp-dyn/content/article/2008/05/19/AR2008051901173.html